- Home
- APRE vs DRCT Comparison
APRE vs DRCT Comparison
Compare APRE & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APRE | DRCT |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0M | 8.9M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | APRE | DRCT |
|---|---|---|
| Price | $0.72 | $0.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $5.50 | ★ $330.00 |
| AVG Volume (30 Days) | ★ 231.3K | 211.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.97 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $62,288,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $58.17 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.55 | $0.04 |
| 52 Week High | $2.65 | $6.04 |
Technical Indicators
Market Signals| Indicator | APRE | DRCT |
|---|---|---|
| Relative Strength Index (RSI) | 41.59 | 41.18 |
| Support Level | $0.55 | $0.36 |
| Resistance Level | $0.98 | $1.96 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 2.44 | 54.29 |
Price Performance
Historical ComparisonAbout APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.